Drug Profile
Anthrax vaccine - Panacea Biotec
Alternative Names: Recombinant anthrax vaccine - Panacea BiotecLatest Information Update: 21 Apr 2016
Price :
$50
*
At a glance
- Originator Jawaharlal Nehru University
- Developer Panacea Biotec
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 20 Apr 2016 No recent reports on development identified - Phase-II for Anthrax (Prevention) in India (Parenteral)
- 01 Jan 2013 Phase-II clinical trials in Anthrax (prevention) in India (Parenteral)
- 01 Jan 2008 Preclinical trials in Anthrax in India (Parenteral)